WO2012017327A3 - Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv - Google Patents

Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv Download PDF

Info

Publication number
WO2012017327A3
WO2012017327A3 PCT/IB2011/002469 IB2011002469W WO2012017327A3 WO 2012017327 A3 WO2012017327 A3 WO 2012017327A3 IB 2011002469 W IB2011002469 W IB 2011002469W WO 2012017327 A3 WO2012017327 A3 WO 2012017327A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
treating
preventing
pharmaceutical composition
diseases caused
Prior art date
Application number
PCT/IB2011/002469
Other languages
French (fr)
Other versions
WO2012017327A2 (en
Inventor
Oleg Iliich Epshtein
Sergey Alexandrovich Tarasov
Original Assignee
Oleg Iliich Epshtein
Sergey Alexandrovich Tarasov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oleg Iliich Epshtein, Sergey Alexandrovich Tarasov filed Critical Oleg Iliich Epshtein
Priority to UAA201300102A priority Critical patent/UA113389C2/en
Priority to EA201300134A priority patent/EA032021B1/en
Publication of WO2012017327A2 publication Critical patent/WO2012017327A2/en
Publication of WO2012017327A3 publication Critical patent/WO2012017327A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition, comprising an activated-potentiated form of an antibody to CD4 receptor, and method of treating and preventing the diseases caused by HIV or associated with HIV, including AIDS..
PCT/IB2011/002469 2010-08-06 2011-07-15 Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv WO2012017327A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
UAA201300102A UA113389C2 (en) 2010-08-06 2011-07-15 Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv
EA201300134A EA032021B1 (en) 2010-08-06 2011-07-15 Pharmaceutical composition and method of treating and preventing the diseases caused by hiv and/or associated with hiv

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010133049/15A RU2010133049A (en) 2010-08-06 2010-08-06 MEDICINAL PRODUCT AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS
RU2010133049 2010-08-06

Publications (2)

Publication Number Publication Date
WO2012017327A2 WO2012017327A2 (en) 2012-02-09
WO2012017327A3 true WO2012017327A3 (en) 2012-04-12

Family

ID=44906251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/002469 WO2012017327A2 (en) 2010-08-06 2011-07-15 Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv

Country Status (5)

Country Link
EA (1) EA032021B1 (en)
FR (1) FR2963562A1 (en)
RU (1) RU2010133049A (en)
UA (1) UA113389C2 (en)
WO (1) WO2012017327A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055518A1 (en) * 2001-12-26 2003-07-10 Goldberg, Evgeny Danilovich Method for curing immunopathosis and medicinal agent for carrying out said method
US20100166762A1 (en) * 2000-06-20 2010-07-01 Oleg Iliich Epshtein Method of treating a pathological syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2192888C1 (en) 2001-02-15 2002-11-20 Эпштейн Олег Ильич Medicinal agent and method of treatment of pathological syndrome
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76641C2 (en) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Homeopathic medicinal agent and method for curing diseases of prostate
US7229648B2 (en) 2003-03-14 2007-06-12 Dreyer Lee R Homeopathic formulations useful for treating pain and/or inflammation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166762A1 (en) * 2000-06-20 2010-07-01 Oleg Iliich Epshtein Method of treating a pathological syndrome
WO2003055518A1 (en) * 2001-12-26 2003-07-10 Goldberg, Evgeny Danilovich Method for curing immunopathosis and medicinal agent for carrying out said method

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JONAS WAYNE B ET AL: "A critical overview of homeopathy", ANNALS OF INTERNAL MEDICINE, NEW YORK, NY; US, US, vol. 138, no. 5, 4 March 2003 (2003-03-04), pages 393 - 399, XP002355318, ISSN: 0003-4819 *
SHANG ET AL: "Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy", THE LANCET, LANCET LIMITED. LONDON, GB, vol. 366, no. 9487, 27 August 2005 (2005-08-27), pages 726 - 732, XP005043950, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(05)67177-2 *
VICKERS A J: "CLINICAL TRIALS OF HOMEOPATHY AND PLACEBO: ANALYSIS OF A SCIENTIFIC DEBATE", JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 6, no. 1, 1 February 2000 (2000-02-01), pages 49 - 56, XP008055722, ISSN: 1075-5535 *

Also Published As

Publication number Publication date
WO2012017327A2 (en) 2012-02-09
FR2963562A1 (en) 2012-02-10
UA113389C2 (en) 2017-01-25
RU2010133049A (en) 2012-02-20
EA032021B1 (en) 2019-03-29
EA201300134A1 (en) 2014-03-31

Similar Documents

Publication Publication Date Title
WO2012017323A3 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv
MY187874A (en) Antibody formulations
MX364229B (en) COMPOSITIONS and METHODS FOR TREATING CARDIOVASCULAR DISEASES.
WO2013046060A9 (en) Paper and methods of making paper
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
WO2012014076A3 (en) Liver organoid, uses thereof and culture method for obtaining them
WO2012100224A3 (en) Preparation of metal-triazolate frameworks
WO2013096380A3 (en) Anti-phf-tau antibodies and their uses
MX356337B (en) Antibodies against human csf-1r and uses thereof.
MX336682B (en) Antibodies against human csf-1r and uses thereof.
WO2012125438A8 (en) Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
WO2013177133A3 (en) Generation of human ips cells by a synthetic self- replicative rna
WO2011113019A3 (en) Ctla4 proteins and their uses
WO2012129341A3 (en) Disease detection in plants
WO2011161226A3 (en) Novel antibody formulation
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
WO2012107416A3 (en) Improved immunotherapy
WO2012148880A3 (en) A method for the preparation of doped single graphene sheets
MX359288B (en) Ivabradine hydrochloride form iv.
WO2012017322A3 (en) Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein
WO2012010509A3 (en) Gel bait for controlling crawling harmful insects
EP2601967A4 (en) Drug and method for the prophylaxis of hiv infection and for the prophylaxis and treatment of diseases caused by or associated with hiv, including aids
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
WO2012047267A3 (en) Polyvalent immunogen
WO2013155338A8 (en) Substituted benzamides and their uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11778687

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201300134

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A201300102

Country of ref document: UA

122 Ep: pct application non-entry in european phase

Ref document number: 11778687

Country of ref document: EP

Kind code of ref document: A2